Literature DB >> 11027950

Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin.

O Hashimoto1, N Kawasaki, K Tsuchida, S Shimasaki, T Hayakawa, H Sugino.   

Abstract

We demonstrate the difference between the follistatin isoforms (FS-288 and FS-315), two activin-binding proteins, in the neutralizing activity for activin signalling. Transcriptional reporter assay using 3TP-Lux, an activin-responsive reporter construct, showed that the inhibitory effect of FS-288 on activin-induced transcriptional response is more potent than that of FS-315. The potency was not influenced by the presence of heparan sulfates, by which FS, in particular FS-288, associates with cell surfaces at a high affinity. Furthermore, FS-288 inhibited the binding of activin to its type II receptor more markedly than did FS-315, as evidenced by surface plasmon resonance and affinity cross-linking experiments. Moreover, the Kd of FS-288 and FS-315 for activin A was estimated to be 46.5+/-0.37 pM and 432+/-26 pM, respectively, by surface plasmon resonance experiments. These results indicate that the different potency between the two FS isoforms in the inhibition of activin activities depends on their affinity for activin A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027950     DOI: 10.1016/s0898-6568(00)00099-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  19 in total

1.  Rapid, efficient isolation of murine gonadotropes and their use in revealing control of follicle-stimulating hormone by paracrine pituitary factors.

Authors:  Joyce C Wu; Pei Su; Nedal W Safwat; Joseph Sebastian; William L Miller
Journal:  Endocrinology       Date:  2004-08-19       Impact factor: 4.736

2.  Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts.

Authors:  Darcie D Seachrist; Emhonta Johnson; Christianne Magee; Colin M Clay; James K Graham; D N Rao Veeramachaneni; Ruth A Keri
Journal:  Biol Reprod       Date:  2012-08-23       Impact factor: 4.285

3.  Expression and purification of recombinant protein related to DAN and cerberus (PRDC).

Authors:  Chandramohan Kattamuri; David M Luedeke; Thomas B Thompson
Journal:  Protein Expr Purif       Date:  2012-02-20       Impact factor: 1.650

Review 4.  Pharmacology of manipulating lean body mass.

Authors:  Patricio V Sepulveda; Ernest D Bush; Keith Baar
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-01       Impact factor: 2.557

Review 5.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

6.  Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass.

Authors:  Se-Jin Lee
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2010

Review 7.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

8.  Prepubertal onset of diabetes prevents expression of renal cortical connective tissue growth factor.

Authors:  William J Langer; Kay Devish; Pamela K Carmines; Pascale H Lane
Journal:  Pediatr Nephrol       Date:  2007-11-21       Impact factor: 3.714

9.  The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.

Authors:  Jennifer N Cash; Carlis A Rejon; Alexandra C McPherron; Daniel J Bernard; Thomas B Thompson
Journal:  EMBO J       Date:  2009-07-30       Impact factor: 11.598

10.  Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells.

Authors:  Kirsten J McTavish; David Nonis; Yvonne D Hoang; Shunichi Shimasaki
Journal:  Mol Cell Endocrinol       Date:  2013-04-06       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.